Cornerstone Capital Management Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-55,500	Closed	-$158K	–	1366
2016 Q2	$158K	Buy	55,500 +49,500	+825%	+$154K	﹤0.01%	1228
2016 Q1	$17K	Sell	6,000 -317	-5%	-$1.41K	﹤0.01%	1447
2015 Q4	$65K	Sell	6,317 -883	-12%	-$8.78K	﹤0.01%	1349
2015 Q3	$82K	Buy	+7,200	New	+$96.1K	﹤0.01%	1353
2015 Q1	–	Sell	-3,700	Closed	-$45K	–	1371
2014 Q4	$45K	Buy	+3,700	New	+$40.9K	﹤0.01%	1211
2013 Q3	–	Sell	-102,600	Closed	-$160K	–	1275
2013 Q2	$160K	Buy	+102,600	New	+$177K	﹤0.01%	1083

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Cornerstone Capital Management Holdings's BCRX Position: Q3 2016 in Review

Cornerstone Capital Management Holdings sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2016, closing a stake of 55,500 shares — an estimated $158K sold.

Cornerstone Capital Management Holdings first reported a position in BCRX in Q2 2013 and held it in 6 quarters. The position peaked at $160K in Q2 2013. 103 funds tracked by Wall St. Rank hold BCRX as of Q3 2016.

Cornerstone Capital Management Holdings reported no remaining BioCryst Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Cornerstone Capital Management Holdings sold 55,500 BioCryst Pharmaceuticals shares in Q3 2016, an estimated $158K.
Cornerstone Capital Management Holdings first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Cornerstone Capital Management Holdings's BioCryst Pharmaceuticals position peaked at $160K in Q2 2013.
103 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2016.

Based on Cornerstone Capital Management Holdings's 13F filing for Q3 2016, filed 16 Nov 2016.